A real-world study showed that prompt SBRT is a viable option that significantly improves the PFS for selected EGFR-mutated nonoligometastatic NSCLC patients with a stable disease during first-line EGFR-TKIs therapy [43]. Here, EGFR is linked to non-small cell lung carcinoma.